Tip: Try a valid symbol or a specific company name for relevant results A pro-grade research workspace with advanced charts, company data and real-time news. Now part of Yahoo Finance Gold.Learn more The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading.
Coinbase pays us for certain activity generated through this link. Prices displayed are informational. Baxter sign on the building in Mississauga, Ontario_ Baxter International Inc_ By JHVEPhoto Baxter International Inc. (BAX), headquartered in Deerfield, Illinois, develops and provides a portfolio of healthcare products.
With a market cap of $11.8 billion, the company develops, manufactures, and markets products and technologies related to hemophilia, immune disorders, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions. The company's products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and research laboratories. Companies worth $10 billion or more are generally described as "large-cap stocks," and BAX perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the medical instruments & supplies industry.
Baxter excels through diversified healthcare products and innovative expansions. Strategic acquisitions enhance its connected care solutions, while investments in new launches and geographic growth solidify its medical technology leadership. Despite its notable strength, BAX shares have slipped 24% from their 52-week high of $30, achieved on Jul. 30.
Over the past three months, BAX stock has gained 14.6%, outperforming the Nasdaq Composite's ($NASX) marginal gains during the same time frame. In the longer term, shares of BAX rose 19.3% on a YTD basis, outperforming NASX's YTD gains of 15.2%. However, the stock dipped 1% over the past 52 weeks, underperforming NASX's 18.3% returns over the last year.
To confirm the bullish trend, BAX has been trading above its 200-day moving average since early June, with slight fluctuations. However, the stock has been trading below its 50-day moving average since early September. BAX's underperformance was largely driven by operational disruptions, margin pressure, and earnings volatility.
Extract — continue reading at the source.
